Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
REGULATORY
Health Minister Vows Thorough Discussions on Drug Pricing, Mentions Policy Veterans’ Proposals
The Japanese government will thoroughly discuss the future of drug pricing rules by receiving input from industry stakeholders, Health Minister Shigeyuki Goto promised at a Diet session on May 12, touching on a series of recent proposals made by policy…
To read the full story
Related Article
- JPMA Chief Sees Free Pricing Proposal as Catalyst for Active Reform Debate
April 5, 2022
- Policy Veterans’ Group Proposes Free Pricing, Chuikyo Re-Pricing Few Years Later
April 4, 2022
- Study Group Launched by Drug Policy Veterans Pushes 6% Adjustment Rate
December 6, 2021
- Ex-MHLW Bureau Chief Calls for 6% Adjustment Rate, Frowns on Macroeconomic Indexing; Study Group Launch Next Month
November 11, 2021
REGULATORY
- Japan to Allow Drone Deliveries of Drugs When Appropriate, Including Powerful Meds
March 29, 2023
- Panel OKs 3 Products for 1st SaMD Priority Review Designations
March 29, 2023
- Japan Diet Enacts Record Budget for FY2023
March 29, 2023
- Ipsen’s Fidrisertib, Chugai’s Faricimab and 2 More APIs Get Orphan Tags in Japan
March 29, 2023
- Japan’s Foreign Minister Likely to Visit China Soon, Demand Citizen’s Release
March 29, 2023
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
The health ministry’s key expert panel on February 15 agreed on the need to consolidate the Japanese generic sector to…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…